Ye Jun, Lin Mei, Zhang Chuanmeng, Zhu Xiaowei, Li Sumeng, Liu Hui, Yin Jianfeng, Yu Hong, Zhu Kuichun
Taizhou People's Hospital, The Center for Translational Medicine, Taizhou, Jiangsu 225300, P.R. China.
Xuzhou Medical University, Department of Pathology, Xuzhou, Jiangsu 221000, P.R. China.
Biomed Rep. 2020 Jul;13(1):43-48. doi: 10.3892/br.2020.1303. Epub 2020 May 12.
Colorectal cancer (CRC) is one of the most common types of cancer in the world, and targeted therapy is frequently used in the clinical management of the disease. A complete and accurate picture of tissue gene mutations is therefore critical. Tissue specimens from 117 patients with CRC were used for high throughput DNA next-generation sequencing (NGS) analysis. Hotspots from 50 genes frequently associated with the development and progression of solid tumors were targeted for sequencing. Characterization of tissue gene mutations was performed; the tissue mutation positive rates of , , , and were 52.1, 19.7, 29.9, 15.4 and 14.5%, respectively. The mutation positive rates of , , , and were 65.8, 39.3, 32.5, 19.7 and 19.7%, respectively. The most frequent mutations were G12A/C/D/S/V, accounting for 61.2% of all mutations. The most frequent mutations were R273C/G/H/L, accounting for 8.5% of all mutations. The most frequent mutation was E1554fs, accounting for 19.7% of all mutations. R132C/H, M541L, N375S, and R361C/H were also frequently identified. mutations were more common in patients ≥60 years old (P<0.05), and mutations were more common in male patients (P<0.05). NGS 50 gene panel sequencing provides a comprehensive tissue gene mutation profile which may significantly improve clinical management.
结直肠癌(CRC)是世界上最常见的癌症类型之一,靶向治疗常用于该疾病的临床管理。因此,全面准确地了解组织基因突变情况至关重要。对117例CRC患者的组织标本进行了高通量DNA二代测序(NGS)分析。针对50个常与实体瘤发生和进展相关的基因热点进行测序。对组织基因突变进行了特征分析; 、 、 、 和 的组织突变阳性率分别为52.1%、19.7%、29.9%、15.4%和14.5%。 、 、 、 和 的突变阳性率分别为65.8%、39.3%、32.5%、19.7%和19.7%。最常见的 突变是G12A/C/D/S/V,占所有 突变的61.2%。最常见的 突变是R273C/G/H/L,占所有 突变的8.5%。最常见的 突变是E1554fs,占所有 突变的19.7%。还经常鉴定出R132C/H、M541L、N375S和R361C/H。 突变在60岁及以上患者中更常见(P<0.05), 突变在男性患者中更常见(P<0.05)。NGS 50基因panel测序提供了全面的组织基因突变谱,可能显著改善临床管理。